Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.

Détails

ID Serval
serval:BIB_1B247BFAA1B8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.
Périodique
Journal of the American College of Cardiology
Auteur(s)
Atar D., Petzelbauer P., Schwitter J., Huber K., Rensing B., Kasprzak J.D., Butter C., Grip L., Hansen P.R., Süselbeck T., Clemmensen P.M., Marin-Galiano M., Geudelin B., Buser P.T.
Collaborateur(s)
F.I.R.E. Investigators
ISSN
1558-3597 (Electronic)
ISSN-L
0735-1097
Statut éditorial
Publié
Date de publication
2009
Volume
53
Numéro
8
Pages
720-729
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
OBJECTIVES: The purpose of this study was to investigate whether FX06 would limit infarct size when given as an adjunct to percutaneous coronary intervention.
BACKGROUND: FX06, a naturally occurring peptide derived from human fibrin, has been shown to reduce myocardial infarct size in animal models by mitigating reperfusion injury.
METHODS: In all, 234 patients presenting with acute ST-segment elevation myocardial infarction were randomized in 26 centers. FX06 or matching placebo was given as intravenous bolus at reperfusion. Infarct size was assessed 5 days after myocardial infarction by late gadolinium enhanced cardiac magnetic resonance imaging. Secondary outcomes included size of necrotic core zone and microvascular obstruction at 5 days, infarct size at 4 months, left ventricular function, troponin I levels, and safety.
RESULTS: There were no baseline differences between groups. On day 5, there was no significant difference in total late gadolinium enhanced zone in the FX06 group compared with placebo (reduction by 21%; p = 0.207). The necrotic core zone, however, was significantly reduced by 58% (median 1.77 g [interquartile range 0.0, 9.09 g] vs. 4.20 g [interquartile range 0.3, 9.93 g]; p < 0.025). There were no significant differences in troponin I levels (at 48 h, -17% in the FX06 group). After 4 months, there were no longer significant differences in scar size. There were numerically fewer serious cardiac events in the FX06-treated group, and no differences in adverse events.
CONCLUSIONS: In this proof-of-concept trial, FX06 reduced the necrotic core zone as one measure of infarct size on magnetic resonance imaging, while total late enhancement was not significantly different between groups. The drug appears safe and well tolerated. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury [F.I.R.E.]; NCT00326976).
Mots-clé
Angioplasty, Balloon, Coronary, Combined Modality Therapy, Double-Blind Method, Electrocardiography, Female, Fibrin Fibrinogen Degradation Products/administration & dosage, Fibrin Fibrinogen Degradation Products/adverse effects, Humans, Injections, Intravenous, Magnetic Resonance Imaging, Male, Middle Aged, Myocardial Infarction/diagnosis, Myocardial Infarction/mortality, Myocardial Reperfusion Injury/prevention & control, Myocardium/pathology, Necrosis, Peptide Fragments/administration & dosage, Peptide Fragments/adverse effects, Thrombolytic Therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
09/10/2011 17:13
Dernière modification de la notice
20/08/2019 13:51
Données d'usage